Skip to main content

Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls


Due to the worldwide COVID-19 outbreak it is mandatory for health care workers to develop containment strategies. Recently published data showed, that cancer patients might have a higher risk for severe course of the disease. We therefore developed a strategy of screening and containment for SARS-CoV-2 for hospitalized cancer patients. Our approach includes a temporary isolation in a so-called floating zone and testing strategy for screening of asymptomatic individuals by pooling of samples before RT-PCR amplification. Patients as far as health care professionals got tested twice a week. Nurses and physicians entered the floating zone with full body protection. Within 8 weeks we tested 418 individuals (professionals and patients) in total. Only 2 patients had COVID-19 without documented further transmission of SARS-CoV-2. We therefore think that our strategy might be a useful approach to protect inpatients with cancer at high risk for SARS-CoV-2 infection during this ongoing pandemic.

Letter to the editor

Over the last few months the world is facing a new coronavirus (SARS-CoV-2) [1] outbreak which started in December 2019 in Wuhan, China [2] and has spread rapidly worldwide. The World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a pandemic on 11th March 2020 [3]. Even though there are ongoing trials for antiviral treatment and vaccine [4], no vaccination to prevent COVID-19 has been approved, yet. Because the most important factor contributing to the morbidity seems to be the exposure to an infection source [5], governments worldwide have been trying to protect the population by implementing measures such as social distancing. Physicians are postponing procedures which are not essential for the survival of patients to protect patients from acquiring infection in hospital and to gain resources of the hospital to treat a higher number of COVID-19 patients.

Cancer patients in general are more susceptible to infections, also due to the partly long-lasting immunosuppressive impact of immunochemotherapy [6], often suffer from comorbidities and often have older age, which are risk factors for severe outcomes [7]. Therefore, patients with cancer might need higher protection during COVID-19 pandemic. Recently published data from China underline these concerns, showing poor outcomes in cancer patients from COVID-19 and a higher risk for cancer patients of developing severe events [8]. Cancer treatment on the other hand can often not be postponed due to the risk of tumor progression. Moreover, patients with other hematologic diseases like myeloproliferative neoplasms treated by JAK inhibitors, or with different inherited types of anemia might be at higher risk.

We therefore developed a strategy of screening and containment for SARS-CoV-2 for hospitalized patients with cancer at our department for hematology and oncology including a hematopoietic stem cell transplant (HSCT) unit, located within a 1250-bed university medical center tertiary care hospital. All newly admitted cancer patients were tested for SARS-CoV-2. The testing is done by standardized Real-Time polymerase chain reaction (RT-PCR) from combined naso-oropharyngeal swab.

Patients at risk of being positive for SARS-CoV2 by clinical symptoms or high-risk exposure were initially isolated on a dedicated ward (COVID-19 ward), until negative results were obtained. All other patients with no specific clinical signs of COVID-19 were isolated in so-called floating zones (Fig. 1), until the test results were available, which are areas with single rooms that are spatially separated from the rest of the ward.

Fig. 1

Patient guidance from the emergency department or planned inpatient admission to the oncology ward

Nurses and physicians entered the floating zone with full body protection including gloves, medical visor, gown and surgical mask. Patients in the floating-zone had to wear a surgical mask, too. After receiving a negative test result, the patients were transferred from the floating zone to the normal care ward. Visits to inpatients were generally prohibited.

Furthermore, all healthcare professionals and patients on our ward (including HSCT unit) were continuously screened for SARS-CoV-2 twice weekly and encouraged to report any symptoms in advance. Joint on-call services with other departments of general internal medicine were discontinued to prevent SARS-CoV2 infection by staff.

Prior to initiating the above measures, all current patients with cancer and the responsible medical personnel were tested for SARS-CoV-2 to have an initial status.

Patients and methods

Over a period of 8 weeks (March 12 to May 3) cancer patients (n = 308) and healthcare professionals (n = 110) were tested individually upon admission and continuously screened twice a week for SARS-CoV-2. Three hundred eight cancer patients were treated at our department during this time period, including 23 patients, who underwent autologous stem cell transplantation, mostly for multiple myeloma and 11 patients, who underwent allogeneic stem cell transplantation, mostly for acute myeloid leukemia (Table 1). Due to the large amount of testing (> 1800), the Institute of Virology developed a standardized testing strategy for screening of asymptomatic individuals by pooling of samples before RT-PCR amplification as recently published to reduce the number of tests needed [9].

Table 1 Tested for SARS-CoV-2 (oncology ward and entire hospital)

During the mentioned period 4162 patients were tested in the entire hospital resulting in an infection rate of 0,65 (Table 1). By the same time 14 healthcare professionals were tested positive for SARS-CoV-2 in the entire hospital without proven virus transmission to a patient. Patients in quarantine needed two sequential negative test results after 10 days from the first positive test result before they could leave the quarantine area.


From a total of 418 individuals (professionals and patients) tested, only 2 patients (infection rate 0,48) were tested positive for SARS-CoV-2 without developing COVID-19 and without further transmission of the virus to other patients or healthcare staff. Both patients were in the floating zone and did not enter the protected oncology wards. No member of our medical staff (oncology unit) got infected with SARS-CoV-2 in contrast to the rapidly rising number of infected people (> 2500) in the area where our hospital is located and in contrast to the rising number of SARS-CoV-2 infections in Germany in general (> 160,000).


However, our approach does have some limitations as it is possible to miss infected individuals due to testing only twice a week.

On the one hand, this strategy can be undermined by failure to comply with the implemented hygienic measures. Besides, another weakness to keep in mind of the strategy described above is the well-known fact that SARS-CoV-2 is not always detectable in nasopharyngeal swabs during the course of disease of infectious patient [10], thus limiting sensitivity and posing a safety risk for strategies based on this method. In symptomatic patients, generous use should be made of CT scans and, in case of suspicious findings, COVID-19 should be assumed, which can be verified by PCR from bronchoalveolar lavage.

Two patients erroneously admitted to our wards illustrate these issues. The first patient (female, 84 years with MDS) was admitted from the emergency department to our ward with fever. Nasopharyngeal swab was obtained in the emergency department and the patient was transferred to our floating zone even though the test result was still pending. After receiving the positive result for SARS-CoV-2 the patient was transferred to the COVID-19 ward. This case led to a new SARS-CoV-2 diagnostic algorithm in the emergency department. The second patient (male, 72 years with history of B-cell lymphoma) was admitted from the emergency department to our ward with fever, myalgia and respiratory symptoms. Nasopharyngeal swab was obtained in the emergency department, and he was transferred to our ward after receiving a negative test result. After a second negative swab and due to ongoing fever despite antibiotic treatment and a highly suspicious CT scan for SARS-CoV-2, he underwent a bronchoalveolar lavage yielding a positive test result for SARS-CoV-2. He was transferred to the COVID-19 ward. In both cases, no transmission of SARS-CoV-2 to other patients or medical staff occurred as demonstrated by serial testing.

These pitfalls clearly illustrate examples of how a testing strategy can fail and point to weaknesses that need further improvement. Nevertheless, our strategy not only allows patients with SARS-CoV-2 to be quickly isolated, thus protecting other vulnerable patients, but also significantly contributed to reduce the fear and anxiety of patients and medical staff. On the contrary, the fact that health care workers are aware of caring for SARS-CoV-2 negative tested patients might give them a false sense of security. This poses the risk that they do not strictly adhere to the hygienic measures which are the same as for untested patients.

We therefore think that our strategy might be a useful approach to protect inpatients with cancer at high risk for SARS-CoV-2 infection during this ongoing pandemic. Especially in cancer patients, these or similar safety measures might be necessary in the longer term, as the success of future vaccination strategies might be limited for parts of our oncological and hematological patients.


  1. 1.

    Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. 2020;382:727–33.

    CAS  Article  Google Scholar 

  2. 2.

    Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2019;579:265–9.

    Article  Google Scholar 

  3. 3.

    World Health Organization. Coronavirus Disease (COVID-19) Outbreak; 2020. [Accessed 30 Apr 2020].

    Google Scholar 

  4. 4.

    Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52:583–9.

    CAS  Article  Google Scholar 

  5. 5.

    Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13.

    CAS  Article  Google Scholar 

  6. 6.

    Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the randomized phase III GALLIUM study: influence of chemotherapy regimen on efficacy and safety. J Clin Oncol. 2018;36:2395–404.

    CAS  Article  Google Scholar 

  7. 7.

    Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.

    CAS  Article  Google Scholar 

  8. 8.

    Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;7534:36383.

    Google Scholar 

  9. 9.

    Lohse S, Pfuhl T, Berkó-Göttel, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis. 2020.

  10. 10.

    Woelfel R, Cormann V, Guggemos G, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020.

Download references


This work is part of the CORSAAR project.



Author information




D.KM., M.A., N.M., S.S., L.T., B.G., St.S. and M.B. contributed to collection, review, and/or analysis of the data; D.KM. wrote the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Dominic Kaddu-Mulindwa.

Ethics declarations

Competing interests

There are no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kaddu-Mulindwa, D., Thurner, L., Bewarder, M. et al. Protection strategy against outbreak of COVID-19 at a tertiary hematology-oncology: strengths and pitfalls. Infect Agents Cancer 16, 17 (2021).

Download citation


  • COVID-19
  • Protection
  • Cancer
  • Strategy
  • Sample pooling